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mGluR theory of Fragile X (reviewed by Bear et al.,
2004). Among them are the findings that (1) activation
of GpI mGluRs with a selective agonist stimulates syn-
aptic protein synthesis and trafficking of FMRP, (2)
many of the lasting functional consequences of GpI
mGluR activation require mRNA translation but not
transcription, and (3) when it has been examined, pro-
tein synthesis-dependent responses to GpI mGluR acti-DOI 10.1016/j.neuron.2005.02.013 vation are exaggerated in the Fmr1 KO mouse, consis-
tent with a role for FMRP as a translational repressor of
selected mRNA transcripts. Considering these findings
together with the known consequences of GpI mGluR
activation in the brain suggested that many of the
symptoms of FXS could be simply accounted for by
o
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s
Fragile X syndrome is the most common heritable w
cause of mental retardation. Previous work has sug- (
gested that overactive signaling by group I metabo- t
tropic glutamate receptors (mGluRs) may be a mech- (
anism underlying many of the disease symptoms. As u
a test of this theory, McBride et al. show that in a Dro- t
sophila model for Fragile X syndrome, treatment with
mGluR antagonists can rescue short-term memory, v
courtship, and mushroom body defects. t
a
i
aFragile X mental retardation syndrome (FXS) is an inher-
wited single-gene disorder. In the afflicted population,
Ithe FMR1 gene is transcriptionally silenced, and the
hFragile X mental retardation protein (FMRP) is not made.
pThe consequence in humans is a diverse constellation
mof psychiatric and neurological symptoms ranging from
fcognitive impairment to autistic behavior (Hagerman
oand Hagerman, 2002). Based on research in the Fmr1
pknockout (KO) mouse, the suggestion was made that
many of these symptoms could be accounted for by
2overactive signaling by group I metabotropic glutamate
areceptors (GpI mGluRs; (Bear et al., 2004; Huber et al.,
m2002). The implication of this “mGluR theory” is that
smany symptoms in FXS might respond to treatment
cwith drugs that inhibit GpI mGluRs (Bear, 2005). In this
i
issue of Neuron, Tom Jongens, Sean McBride, and col-
s
leagues (McBride et al., 2005) describe an audacious
a
test of this notion in fruit flies lacking dfmr1, the Dro- u
sophila homolog of human FMR1. Mutant flies exhibit f
altered courtship behavior, decreased memory in a t
conditioned courtship assay, and alterations in the w
structure of the brain (the mushroom bodies). Remarka- p
bly, feeding flies drugs that target mammalian mGluR d
signaling could rescue all three defects. These amazing 2
results fuel a growing sense of optimism that appropri-
ate pharmacological intervention could ameliorate, and a
possibly even cure, aspects of Fragile X syndrome in w
humans. t
In mammals, mGluRs comprise a family of eight sub- i
types that are commonly divided into three groups p
based on their shared signal transduction pathways p
(Conn and Pin, 1997). Group I mGluRs consist of w
mGluR1 and mGluR5 and couple to phospholipase C o
(PLC), which stimulates the turnover of membrane pho- m
sphoinositides. Several lines of research led to theveractive mGluR signaling (Figure 1A). Because mGluR1
s necessary for proper cerebellar function, mGluR5 has
een viewed as the better therapeutic target. There are
everal drugs that selectively inhibit mGluR5; the most
idely used is the noncompetitive antagonist MPEP
2-methyl-6-phenylethynyl-pyridine), with the caveat
hat at high concentrations it blocks NMDA receptors
Spooren et al., 2001). MPEP was the first food additive
sed by McBride et al. to treat the behavioral and struc-
ural deficits in Fragile X flies.
Courtship behavior in Drosophila is innate and in-
olves a complex set of behaviors that ends in copula-
ion (Figure 2A). Conditioned courtship suppression is
n associative learning assay that modifies this set of
nnate behaviors. Briefly, the conditioning paradigm is
s follows. During the training phase, the male is placed
ith an unreceptive trainer (a previously mated female).
nitially, he courts the female vigorously, but over time
is courtship activity declines (Figure 2B). In the next
hase, his memory is tested with a receptive virgin fe-
ale. After training, wild-type males will not court this
emale, even though she is receptive. This suppression
f courtship lasts 2–3 hr and constitutes the memory
hase (Figure 2C).
As had been previously reported (Dockendorff et al.,
002) dfmr1 KO flies show diminished innate courtship
ctivity (Figure 2A): KO flies court receptive virgin fe-
ales less vigorously than wild-types. In the current
tudy, McBride et al. extend the analysis to conditioned
ourtship suppression. They find that during the train-
ng phase (Figure 2B) KO flies show normal courtship
uppression, indicating that learning is intact in these
nimals. However, courtship suppression memory (Fig-
re 2C) is disrupted: KO flies continue to court tester
emales at naive levels after exposure to unreceptive
rainer females. These behavioral changes correlate
ith an anatomical defect in the mushroom body, the
art of the fly brain believed to be responsible for con-
itioned courtship learning and memory (Michel et al.,
004).
Pharmacological rescue of all three phenotypes was
chieved by feeding KO animals MPEP. Maximal rescue
as obtained when treatment began in larvae and con-
inued in adults, suggesting a role for mGluR signaling
n both the development and adult expression of the
henotypes. The courtship and conditioned courtship
henotypes could still be rescued when treatment was
ithheld until adulthood. The mushroom body defect,
n the other hand, could only be rescued when treat-
ent began early, suggesting that this structuralchange is a consequence of an altered developmental
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643trajectory that cannot be reversed in adults. However,
these findings taken together indicate that normal
mushroom body anatomy is not required for rescue of
the behavioral phenotype. The exciting implication is
that pharmacotherapy in early development (which
might correspond to a human developmental epoch
earlier than the disease is identified) may not be neces-
sary for recovery of a cognitive disruption.
The findings summarized above appear to provide
stunning support for the mGluR theory. However, the
audacity of Jongens’ study stems from the fact that
other than the MPEP binding region, the lone functional
mGluR in the Drosophila genome (DmGluRA) bears
little resemblance to mammalian mGluR5. In fact,
DmGluRA is an ortholog of vertebrate group II mGluRs
that are negatively coupled to adenyl cyclase (AC). In-
deed, McBride et al. were able to show that three dif-
ferent group II-selective, competitive mGluR antago-
nists and lithium chloride also rescue the Fragile X
phenotype. Because all four antagonists showed the
same effects, the authors argue that DmGluRA is the
relevant target. However, future studies to unequivo-
cally establish the role of mGluR activity in pathogene-
sis must show that reduction in DmGluRA gene dosage
(by mutation or RNAi) rescues the dfmr1-KO pheno-
types and occludes drug effects.
It is possible that DmGluRA in Drosophila assumes
the full burden of metabotropic glutamate signaling that
is divided among the eight different mGluRs in verte-
brates. Indeed, the Drosophila data are compatible with
the mGluR theory as it is currently articulated if there
exist pathways that couple DmGluRA activation to
FMRP-regulated protein synthesis (Figure 1B). CurrentFigure 1. The mGluR Theory of Fragile X
(A) In mammals, many lasting consequences of activating group I
mGluRs (mGluRs 1 and 5) require local mRNA translation and ap-
pear to be exaggerated in the absence of FMRP. Rather than the
“classical” signaling via phospholipase C (PLC), these protein syn-
thesis-dependent actions of mGluR stimulation appear to require
activation of extracellular signal-regulated kinase (ERK). (B) In the
fly, McBride et al. find that drugs blocking the effect of glutamate
at the Drosophila mGluR (DmGluRA) can rescue deficits caused
by the absence of FMRP. Although DmGluRA resembles vertebrate
group II mGluRs that signal via inhibition of adenylyl cyclase (AC),
these findings are consistent with the mGluR theory if pathways
exist that couple DmGluRA activation to FMRP-regulated protein
synthesis.data in mammals suggest that GpI mGluRs stimulateprotein synthesis via activation of extracellular signal-
regulated kinase (ERK; Gallagher et al., 2004; Zhao et
al., 2004), rather than the “classical” pathway involving
phosphoinositide turnover (and a known target of lith-
ium). It is obviously of great interest to know if
DmGluRA activation stimulates mRNA translation in
flies and how this is regulated by mGluR antagonists,
lithium, and FMRP. This knowledge will be important in
making predictions about how the findings in flies
might generalize to humans with Fragile X. In the mean-
time, however, the current study provides a compelling
demonstration that pharmacotherapy has the potential
to cure aspects of Fragile X.
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